Ukr.Biochem.J. 2022; Volume 94, Issue 6, Nov-Dec, pp. 11-17


The role of microRNA-613 and its related genes in ovarian cancer

M. M. Mohammed, M. M. Ramzy*, S. S. Gaber,
H. A. Mohamed, M. R. Mohamed, A. M. Abdalla

Department of Biochemistry, Faculty of Medicine, Minia University, Egypt;

Received: 19 October 2022; Revised: 25 November 2022;
Accepted: 17 February 2023; Available on-line: 27 February 2023

Ovarian cancer (OC) is the most lethal gynecological cancer. Multiple genetic and epigenetic abnormalities have been detected in ovarian cancers. As microRNAs (miRNAs) play important roles in carcinogenesis, numerous researchers aim to determine the molecular mechanism that regulates the cancer cells proliferation and metastasis. In the current study, the expression of microRNA-613 and related KRAS and Ezrin genes was assessed by Real-time PCR in ovarian cancer tissue and the adjacent apparently normal tissues. Our results revealed that the expression of miRNA-613 was downregulated in ovarian cancer while the expression of KRAS and Ezrin was higher in cancer tissues compared to apparently normal ovarian tissues. There was a negative correlation between the expression of miRNA-613 and both KRAS and Ezrin genes expression and a positive correlation between KRAS and Ezrin gene expression. The results obtained confirm that miRNA-613 acts as a tumor-suppressive gene in ovarian cancer and can realize such impact through the expression of KRAS and Ezrin genes. These data contribute to the identification of potential biomarkers and novel targets for OC early detection and treatment.

Keywords: , , , ,


  1. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. PubMed, CrossRef
  2. Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11-27. PubMed, CrossRef
  3. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomark Cancer. 2019;11:1179299X19860815. PubMed, PubMedCentral, CrossRef
  4. Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15(1):48. PubMed, PubMedCentral, CrossRef
  5. Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Devel Ther. 2017;11:2871-2890. PubMed, PubMedCentral, CrossRef
  6. Oliveto S, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. World J Biol Chem. 2017;8(1):45-56. PubMed, PubMedCentral, CrossRef
  7. Braicu C, Buiga R, Cojocneanu R, Buse M, Raduly L, Pop LA, Chira S, Budisan L, Jurj A, Ciocan C, Magdo L, Irimie A, Dobrota F, Petrut B, Berindan-Neagoe I. Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression. J Exp Clin Cancer Res. 2019;38(1):433. PubMed, PubMedCentral, CrossRef
  8. Mei J, Xu R, Hao L, Zhang Y. MicroRNA-613: A novel tumor suppressor in human cancers. Biomed Pharmacother. 2020;123:109799. PubMed, CrossRef
  9. Zannoni GF, Improta G, Chiarello G, Pettinato A, Petrillo M, Scollo P, Scambia G, Fraggetta F. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch. 2014;465(2):193-198. PubMed, CrossRef
  10. Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA, Schirmacher P, Hoffmann H, Muley T, Weichert W. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J. 2014;43(3):872-883. PubMed, CrossRef
  11. Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget. 2017;9(5):6630-6643. PubMed, PubMedCentral, CrossRef
  12. Mullard A. Cracking KRAS. Nat Rev Drug Discov. 2019;18(12):887-891. PubMed, CrossRef
  13. Wu Z, Qi Y, Guo Z, Li P, Zhou D. miR-613 suppresses ischemia-reperfusion-induced cardiomyocyte apoptosis by targeting the programmed cell death 10 gene. Biosci Trends. 2016;10(4):251-257. PubMed, CrossRef
  14. Li N, Kong J, Lin Z, Yang Y, Jin T, Xu M, Sun J, Chen L. Ezrin promotes breast cancer progression by modulating AKT signals. Br J Cancer. 2019;120(7):703-713. PubMed, PubMedCentral, CrossRef
  15. Li MJ, Xiong D, Huang H, Wen ZY. Ezrin Promotes the Proliferation, Migration, and Invasion of Ovarian Cancer Cells. Biomed Environ Sci. 2021;34(2):139-151. PubMed, CrossRef
  16. Auvinen E, Carpen O, Korpela T, Ronty M, Vaheri A, Tarkkanen J. Altered expression of ezrin, E-Cadherin and β-Catenin in cervical neoplasia. Neoplasma. 2013;60(1):56-61. PubMed, CrossRef
  17. Song Y, Ma X, Zhang M, Wang M, Wang G, Ye Y, Xia W. Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review. Front Cell Dev Biol. 2020;8:588801. PubMed, PubMedCentral, CrossRef
  18. Bancroft JD, Gamble M. (2008). Theory and practice of histological techniques. Elsevier Health Sciences, 2008. 725 p.
  19. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turk Ger Gynecol Assoc. 2019;20(1):47-54. PubMed, PubMedCentral, CrossRef
  20. Dong Y, Wei MH, Lu JG, Bi CY. Long non-coding RNA HULC interacts with miR-613 to regulate colon cancer growth and metastasis through targeting RTKN. Biomed Pharmacother. 2019;109:2035-2042. PubMed, CrossRef
  21. Zhou N, He Z, Tang H, Jiang B, Cheng W. LncRNA RMRP/miR-613 axis is associated with poor prognosis and enhances the tumorigenesis of hepatocellular carcinoma by impacting oncogenic phenotypes. Am J Transl Res. 2019;11(5):2801-2815. PubMed, PubMedCentral
  22. Xue M, Li G, Sun P, Zhang D, Fang X, Li W. MicroRNA-613 induces the sensitivity of gastric cancer cells to cisplatin through targeting SOX9 expression. Am J Transl Res. 2019;11(2):885-894. PubMed, PubMedCentral
  23. Jiang C, Yang Y, Yang Y, Guo L, Huang J, Liu X, Wu C, Zou J. Long Noncoding RNA (lncRNA) HOTAIR Affects Tumorigenesis and Metastasis of Non-Small Cell Lung Cancer by Upregulating miR-613. Oncol Res. 2018;26(5):725-734. PubMed, PubMedCentral, CrossRef
  24. Xiong H, Yan T, Zhang W, Shi F, Jiang X, Wang X, Li S, Chen Y, Chen C, Zhu Y. miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. Cell Signal. 2018;44:33-42. PubMed, CrossRef
  25. Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R, Huang X. MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene. 2018;659:168-174. PubMed, CrossRef
  26. Su X, Gao C, Feng X, Jiang M. miR-613 suppresses migration and invasion in esophageal squamous cell carcinoma via the targeting of G6PD. Exp Ther Med. 2020;19(4):3081-3089. PubMed, PubMedCentral, CrossRef
  27. Fu X, Cui Y, Yang S, Xu Y, Zhang Z. MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS. Tumour Biol. 2016;37(5):6477-6483. PubMed, CrossRef
  28. Kang K, Zhang J, Zhang X, Chen Z. MicroRNA-326 inhibits melanoma progression by targeting KRAS and suppressing the AKT and ERK signalling pathways. Oncol Rep. 2018;39(1):401-410. PubMed, CrossRef
  29. Luo J, Jin Y, Li M, Dong L. Tumor suppressor miR‑613 induces cisplatin sensitivity in non‑small cell lung cancer cells by targeting GJA1. Mol Med Rep. 2021;23(5):385. PubMed, PubMedCentral, CrossRef
  30. Sideris M, Emin EI, Abdullah Z, Hanrahan J, Stefatou KM, Sevas V, Emin E, Hollingworth T, Odejinmi F, Papagrigoriadis S, Vimplis S, Willmott F. The Role of KRAS in Endometrial Cancer: A Mini-Review. Anticancer Res. 2019;39(2):533-539. PubMed, CrossRef
  31. Tameishi M, Ishikawa H, Tanaka C, Kobori T, Urashima Y, Ito T, Obata T. Ezrin Contributes to the Plasma Membrane Expression of PD-L1 in A2780 Cells. J Clin Med. 2022;11(9):2457. PubMed, PubMedCentral, CrossRef
  32. Ghaffari A, Hoskin V, Turashvili G, Varma S, Mewburn J, Mullins G, Greer PA, Kiefer F, Day AG, Madarnas Y, SenGupta S, Elliott BE. Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. Breast Cancer Res. 2019;21(1):12. PubMed, PubMedCentral, CrossRef
  33. Köbel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol. 2006;25(2):121-130. PubMed, CrossRef
  34. Li J, Wei K, Yu H, Jin D, Wang G, Yu B. Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis. Sci Rep. 2015;5:17903. PubMed, PubMedCentral, CrossRef
  35. Cihan YB. Does ezrin play a predictive role in cancer patients undergoing radiotherapy and/or chemotherapy? Hum Pathol. 2018;80:247-248. PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.